Publication date: Jun 20, 2024
In developing tuberculosis vaccines, scientists have studied proteins from M. tuberculosis that trigger the protective immunity against tuberculosis. Actually BCG is very effective in preventing tuberculosis in children, creating a booster vaccine to strengthen immunity in adults is considered a promising and realistic option. Furthermore, many of vaccine studies ignore the native three-dimensional structure of the proteins and the modification they undergo after being translated in M. tuberculosis. To evaluate MDP1 for a tuberculosis booster vaccine, Ozeki et al. Tuberculosis is still one of the deadliest infectious diseases, causing over one million deaths each year worldwide. However, no new vaccine has yet surpassed BCG, which is a highly effective live vaccine. Importantly, mMDP1 demonstrated a superior capacity for IFN-gamma production compared to other vaccine candidate antigens, such as Antigen 85 complex, which is currently in development.
| Concepts | Keywords |
|---|---|
| Cultured | Adults |
| Dna | Al |
| Tuberculosis | Bcg |
| Vaccinated | Candidate |
| Gamma | |
| Ifn | |
| Mdp1 | |
| Mmdp1 | |
| Modifications | |
| Post | |
| Translational | |
| Tuberculosis | |
| Vaccinated | |
| Vaccine | |
| Vaccines |
Semantics
| Type | Source | Name |
|---|---|---|
| pathway | KEGG | Tuberculosis |
| disease | MESH | tuberculosis |